MK-1167
/ Merck (MSD), Bionomics
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
February 12, 2025
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
(GlobeNewswire)
- "Neuphoria Therapeutics Inc...announced today that the Company is due to receive a $15 million milestone payment from Merck...The payment is triggered by the initiation, by Merck, of a Phase 2 clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM), for the treatment of the symptoms of Alzheimer’s disease dementia (NCT06721156)...This $15M payment marks the second milestone achieved in the collaboration with Merck. Under the agreement, Neuphoria is eligible to receive up to $450M in additional milestone payments for certain development and commercial milestones associated with the progress of multiple candidates plus royalties on net sales of any licensed medicines."
Financing • Alzheimer's Disease • Dementia
December 26, 2024
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
(clinicaltrials.gov)
- P2 | N=350 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting
Enrollment open • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
December 06, 2024
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
(clinicaltrials.gov)
- P2 | N=350 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC
New P2 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
November 25, 2024
A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)
(clinicaltrials.gov)
- P1 | N=16 | Completed | Sponsor: Merck Sharp & Dohme LLC
New P1 trial
October 03, 2024
A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)
(clinicaltrials.gov)
- P1 | N=16 | Completed | Sponsor: Merck Sharp & Dohme LLC
New P1 trial
September 26, 2024
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
(clinicaltrials.gov)
- P1 | N=28 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed
Trial completion • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
August 07, 2024
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
(clinicaltrials.gov)
- P1 | N=28 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting
Enrollment closed • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
June 28, 2024
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
(clinicaltrials.gov)
- P1 | N=28 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | N=16 ➔ 28
Enrollment change • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
April 03, 2024
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
(clinicaltrials.gov)
- P1 | N=16 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting
Enrollment open • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
February 29, 2024
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
(clinicaltrials.gov)
- P1 | N=16 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC
New P1 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
1 to 10
Of
10
Go to page
1